Single vs Double Bevacizumab Injections Compared for Macular Degeneration Treatment
A Phase 4 RCT tests whether one bevacizumab injection matches two combined doses for neovascular AMD outcomes over 12 months.
Summary
This completed Phase 4 clinical trial from the University Hospital of Ferrara compared two treatment strategies for neovascular age-related macular degeneration (NV-AMD). Patients were randomized to receive either a single intravitreal bevacizumab injection (IVIBx1) or two combined injections spaced about 30 days apart (IVIBx2), both given on a pro-re-nata (as-needed) basis. The trial aimed to determine whether the simpler single-injection regimen was non-inferior to the combined approach in terms of safety, visual outcomes, number of injections required, patient compliance, and vision-related quality of life over 12 months. This research has practical implications for reducing treatment burden on patients and healthcare systems while maintaining therapeutic effectiveness for a leading cause of vision loss in older adults.
Detailed Summary
Age-related macular degeneration is the leading cause of irreversible vision loss in adults over 50, and its neovascular form — driven by abnormal blood vessel growth stimulated by vascular endothelial growth factor (VEGF) — requires ongoing intravitreal injections to preserve sight. Bevacizumab, an anti-VEGF agent originally developed for cancer, is widely used off-label for this condition due to its cost-effectiveness compared to approved alternatives like ranibizumab or aflibercept.
This Phase 4 randomized controlled trial, sponsored by the University Hospital of Ferrara and supported by the Emilia-Romagna Regional Healthcare Fund, enrolled patients with NV-AMD who were either treatment-naive or already receiving pro-re-nata (PRN) anti-VEGF therapy. Participants were randomized 1:1 to a single bevacizumab injection per treatment cycle (IVIBx1) or two injections spaced 30 ± 10 days apart per cycle (IVIBx2), with retreatment triggered by signs of persistent neovascular activity.
The primary objective was to establish non-inferiority of the single-injection regimen versus the combined protocol across measures of clinical safety, therapeutic efficacy, total injection burden, patient compliance, and vision-related quality of life over 12 months of follow-up. The open-label parallel-arm design reflects real-world clinical practice at the Ferrara Eye Clinic.
If the single-injection protocol proves non-inferior, it could meaningfully reduce the treatment burden for patients — fewer clinic visits, lower procedural risk, and reduced healthcare costs — without compromising visual outcomes. This is particularly relevant given the chronic, lifelong nature of NV-AMD management.
However, the trial's open-label design introduces potential bias, and results are not yet published in peer-reviewed literature. The summary here is based solely on the registry abstract, so key outcome data, statistical results, and adverse event profiles remain unavailable for evaluation.
Key Findings
- Trial tests whether single bevacizumab injections are non-inferior to double injections for NV-AMD over 12 months.
- Both arms used pro-re-nata dosing, retreating only when neovascular activity persisted on monitoring.
- Outcomes assessed include visual acuity, injection frequency, safety, compliance, and quality of life.
- Reducing injections per cycle could lower procedural risk and healthcare costs without sacrificing efficacy.
- Trial is completed but peer-reviewed results have not yet been published based on available information.
Methodology
This is a Phase 4 randomized controlled open-label trial with parallel arms and 1:1 allocation, conducted at the University Hospital of Ferrara Eye Clinic. Patients with NV-AMD were randomized to single (IVIBx1) or combined double (IVIBx2) intravitreal bevacizumab injections on a pro-re-nata schedule, with 12 months of follow-up. The primary statistical framework is non-inferiority comparison of the single-injection regimen versus the combined regimen.
Study Limitations
This summary is based on the clinical trial registry abstract only, as the full study results and peer-reviewed publication are not available, so no outcome data can be assessed. The open-label design introduces potential performance and detection bias. The trial was conducted at a single Italian center, which may limit generalizability to other populations and healthcare systems.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: